1. Interaction of Purine and its Derivatives with A1, A2-Adenosine Receptors and Vascular Endothelial Growth Factor Receptor-1 (Vegf-R1) as a Therapeutic Alternative to Treat Cancer
   Lauro Figueroa et al, 2024, Drug Research CrossRef
2. Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells
   Andrea M. Chambers et al, 2018, Frontiers in Immunology CrossRef
3. The antitumor effect of LJ-529, a novel agonist to A3 adenosine receptor, in both estrogen receptor–positive and estrogen receptor–negative human breast cancers
   Heekyoung Chung et al, 2006, Molecular Cancer Therapeutics CrossRef
4. Recent Progress of Adenosine Receptor Modulators in the Development of Anticancer Chemotherapeutic Agents
   Sarapynbiang Marwein et al, 2019, Current Pharmaceutical Design CrossRef
5. Adenosine Receptors as Novel Targets for the Treatment of Various Cancers
   Bapi Gorain et al, 2019, Current Pharmaceutical Design CrossRef
6. The Effects of CD73 on Gastrointestinal Cancer Progression and Treatment
   Pengcheng Sun et al, 2022, Journal of Oncology CrossRef
7. Combined cancer immunotherapy based on targeting adenosine pathway and PD-1/PDL-1 axis
   Mehrdad Fathi et al, 2024, Expert Opinion on Therapeutic Targets CrossRef
8. Adenosinergic Signaling Alters Natural Killer Cell Functional Responses
   Andrea M. Chambers et al, 2018, Frontiers in Immunology CrossRef
9. Role and Function of Adenosine and its Receptors in Inflammation, Neuroinflammation, IBS, Autoimmune Inflammatory Disorders, Rheumatoid Arthritis and Psoriasis
   Ashok K. Shakya et al, 2019, Current Pharmaceutical Design CrossRef